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Abstract: The marine plathyhelminth Macrostomum lignano was recently isolated from 
Adriatic shore sediments where it experiences a wide variety of environmental challenges, 
ranging from hypoxia and reoxygenation, feeding on toxic algae, to exposure to 
anthropogenic contaminants. As multidrug resistance transporters constitute the first line of 
defense against toxins and toxicants we have studied the presence of such transporters in 
M. lignano in living animals by applying optical methods and pharmacological inhibitors 
that had been developed for mammalian cells. Application of the MDR1 inhibitor 
Verapamil or of the MRP1 inhibitors MK571 or Probenecid increased the intracellular 
fluorescence of the reporter dyes Fura-2 am, Calcein am, Fluo-3 am in the worms, but did 
not affect their staining with the dyes Rhodamine B, CMFDA or Ageladine A. The marine 
sponge alkaloid Ageladine A remained intracellularly trapped for several days in the 
worms, suggesting that it does not serve as substrate of multidrug resistance exporters. In 
addition, Ageladine A did not affect multidrug resistance-associated protein (MRP)-mediated 
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dye export from M. lignano or the MRP1-mediated glutathione (GSH) export from 
cultured rat brain astrocytes. The data obtained demonstrate that life-imaging is a useful 
tool to address physiological drug export from intact marine transparent flatworms by 
using multiphoton scanning microscopy. 
Keywords: 2-photon laser scanning microscopy; natural product; fluorescence;  
live imaging; ABC transporter 
 
1. Introduction 
The marine plathyhelminth Macrostomum lignano, presumably endemic to the Adriatic Sea, was 
described as a new species by Ladurner and colleagues in 2005 [1]. The flatworm inhabits shallow 
water sediments of the relative warm Adriatic Sea, where it experiences periods of hypoxia of variable 
length and subsequent reoxigenation, as well as possibly toxin exposure from its diatom diet. 
Additionally, in Adriatic shore sediments, the species may be exposed to different contaminants from 
anthropogenic sources. Thus, it is evident that M. lignano lives in a challenging environment, which 
requires organismic and cellular defense systems. 
Secondary metabolites are a diverse group of organic compounds different from primary 
metabolites, they are not directly involved in development, growth, or reproduction but rather have 
allelochemical function. In some cases these functions are well defined within the competitive arms 
race or as feeding repellents, trail markers, sexual hormones, or antifouling substances (e.g., [2,3]). 
Some marine organisms are especially rich in secondary metabolites with important biological activity. 
Environmental stress such as predation, competition for space, and overgrowth is assumed to be the 
reason for the development of highly bioactive secondary metabolites for chemical defense in  
sponges [4]. The compound Ageladine A is a biological active brominated pyrrole-imidazole alkaloid, 
which was firstly isolated from the Papua New Guinean sponge Agelas nakamurai by Fujita and 
colleagues [5]. Three years after the first description of Ageladine A, Meketa and Weinreb [6] and 
Shengule and Karuso [7] developed a protocol for synthesizing the alkaloid which was further 
optimized [8,9]. Ageladine A shows intense fluorescence during UV-excitation [5,10], which was later 
demonstrated to be pH-dependent and applicable as a membrane permeable dye for staining of isolated 
cells and transparent organisms [10–13]. Several investigations of its bioactivity revealed an inhibitory 
effect on angiogenesis [5,14]. 
Cellular transport mechanisms, which export substances from the cellular interior, constitute an 
important defense line of cells and organisms against toxic compounds. Multidrug resistance 
transporters in eukaryotes belong to the superfamily of ABC-transporters, which are named after  
their most characteristic feature, the highly conserved ATP-binding cassette [15]. The major  
ABC-transporters involved in multidrug resistance in cancer cells are P-glycoprotein (MDR1, P-gp, 
ABCB1), multidrug resistance-associated proteins (MRPs, belonging to the ABCC sub-family), and 
the breast cancer resistance proteins (BRCP1, ABCG2). The most intensively investigated  
multidrug resistance transporter is the 170 kDa MDR1, which was first described as a surface 
phosphoglycoprotein in a hamster cell line [16]. MDR1 plays a major role in protecting cells against 
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toxic agents, mainly in the liver, the kidney, and the brain [17,18]. Expressed in endothelial cells of the 
blood-brain-barrier, MDR1 is involved in preventing the permeation of drugs and toxic agents into the 
central nervous system [18]. MDR1 transports hydrophobic and amphipathic compounds, including 
cancer drugs like Colchicine, Vinblastine, and Paclitaxel [19]. The 190 kDa MRP1, the first described 
member of the multidrug resistance associated proteins (MRP) family, was originally cloned from a 
human multidrug resistance lung cancer line [17]. MRP1 mediates the transport of glutathione-, 
glucuronate-, and sulfate-conjugated as well as of unconjugated organic, anionic drugs and dyes [20]. 
Furthermore, MRP1 transports neutral as well as basic drugs. MRP2 and MRP3 also mediate the 
transport of glutathione conjugated toxins [21]. Although several isoforms of MRPs have been studied 
in the last decades, none have been associated as clearly with multidrug resistance as MRP1 [21,22]. 
Specific inhibitors for multidrug resistance transporters applicable in cancer patients, animals, and 
living cells are rare [21]. Verapamil was one of the first compounds to be identified as a not very 
specific inhibitor for P-glycoproteins [23]. Its presence enhances the accumulation of some anti-cancer 
drugs in MDR1-expressing model systems [24]. It is known that fluorescence dyes like Calcein am, 
Fluo-3 am, and Fura-2 am are actively extruded by MDR1 [25,26]. Therefore, they are well suited as 
reporter dyes to show the inhibitory effect of Verapamil on MDR1-mediated transport. MRPs are 
inhibited by Probenecid and Vinca alkaloids [27,28]. Gollapudi et al. showed that Probenecid reversed 
multidrug resistance in a cancer cell line by the modulation of the MRP-mediated drug transport [29]. 
MK571, a leukotriene D4-receptor antagonist, was shown to be a highly specific MRP1 inhibitor in 
clinical vesicular transport experiments [30]. By measuring the efflux of Calcein am, Fluo-3 am, and  
Fura-2 am, the inhibitory effect of Probenecid and MK517 can be determined since all three 
fluorescent dyes are actively transported by MRPs [31–34]. 
Human MRP and MDR homologues have been described in a wide variety of evolutionary early 
organisms, from plants, yeast, and different types of worms, including parasites. Sato et al. [35] 
demonstrated the presence of a MRP homologue in the protonephridial epithelium of the 
platythelminth Schistosoma mansoni. In aquatic animals, as well as in parasites, the whole body may 
be exposed to toxins or toxicants. The mechanisms of multidrug resistance in marine sponges, 
freshwater fish, and both freshwater and marine mussels are similar to multidrug resistance in human 
cancer cells [36]. Homologues of MDR1 and MRPs can be found for example in crustaceans [34,37], 
fish [38], mussels and diatoms [39–41]. 
Prior to this study, experiments were performed to estimate the pH values in tissues and cells of 
marine transparent animals (jellyfish, sea anemone, flatworm) by using the alkaloid Ageladine A as a 
pH sensitive fluorescence dye [10,11]. Remarkably, the fluorescent signal of Ageladine A was still 
detectable in the worms even several days post-staining. The question arose whether Ageladine A is 
fluorescing in the animal tissues longer than some other common fluorescent dyes, and if so, what 
could be the mechanism behind the persistent fluorescence. We hypothesized that Ageladine A 
fluorescence may be maintained by an inhibition of multidrug-resistance transporter-mediated export 
from the worms, possibly induced by the alkaloid itself. Therefore, we investigated the uptake and 
removal of reporter dyes under the influence of Ageladine A. 
M. lignano is easy to culture, and due to its small size and transparency, it is a good candidate for 
optical investigations of living, undisturbed animals. By using multiphoton scanning microscopy, we 
have investigated whether homologues of MDR1 and MRPs are functionally expressed in the flatworm 
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and whether Ageladine A may function as an inhibitor or substrate of such transporters. For the latter 
question, rat astrocytes were used as an established MRP1-expressing model [22] in a comparative 
approach. This is the first study addressing the presence, physiology, and substrate specificity of 
multidrug-resistance transporters in M. lignano. 
2. Results 
Ageladine A stains complete M. lignano individuals with the highest fluorescence coinciding with 
the rhabdites and some parts around the mouth (Figure 1). Due to the properties of Ageladine A, these 
areas are assumed to be the most acidic regions/organs [12]. Individual stainings with Ageladine A and 
Rhodamine B lasted more than 6 days after a short incubation period of roughly 2 h, whereas  
Fura-2 am and Fluo-3 am staining was maintained only during day 1. 
Figure 1. CFLSM scan of two individuals of M. lignano stained with Ageladine A 
(fluorescence is shown in false color). Ageladine A shows a pH-depending fluorescence. 
Highly fluorescent areas (white) are more acidic than dark areas (dark red). (A) Scan of the 
whole body. (B) Section of reproductive organs. 
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We used three different dyes for the reporter assay: Calcein am, Fluo-3 am and Fura-2 am. Living 
worms were incubated with these dyes in the presence and absence of the MDR1 inhibitor Verapamil. 
Staining with all dyes was improved by Verapamil, indicating the involvement of a  
Verapamil-sensitive transporter in the export of these dyes (Figure 2A–C). Rhodamine B and CMFDA 
as well as Ageladine A stained the animals, but the addition of Verapamil did not affect the staining 
intensity (Figure 2D–F). This indicates that Ageladine A, Rhodamine B and CMFDA are not exported 
by MDR1 transporters. 
Figure 2. Effects of the MDR1-inhibitor Verapamil on the fluorescence of dye-treated  
M. lignano. The worms were exposed to the fluorescence dyes Calcein am (5 μM, A), 
Fluo-3 am (5 μM, B), Fura-2 am (5 μM, C), Ageladine A (5 μM, D), CMFDA (10 μM, E) 
or Rhodamine B (5 μM, F), in the absence or presence of Verapamil (Ver, 25 µM).  
* p < 0.05, ** p < 0.01, *** p < 0.001 (Student’s t-test). 
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Presence of the MRP1 transport inhibitor MK571 increased the fluorescence of Fura-2, Fluo-3, and 
Calcein (Figure 3A–C), indicating presence of a MK571 sensitive transporter in M. lignano. In 
contrast, MK571 did not increase the fluorescence of worms treated with Rhodamine B, Ageladine A 
or CMFDA (Figure 3D–F), suggesting that theses dyes are not substrates of a MRP-homologue in  
M. lignano. Similar results were obtained with the less specific MRP inhibitor Probenecid  
(data not shown). 
Figure 3. Effects of the MRP-inhibitor MK571 on the fluorescence of dye-treated  
M. lignano. The worms were exposed to the fluorescence dyes Calcein am (5 μM, A), 
Fura-2 am (5 μM, B), Fluo-3 am (5 μM, C), Ageladine A (5 μM, D), Rhodamine B  
(5 μM, E), or CMFDA (10 µM, F) in the absence or presence of MK571 (MK, 50 µM). 
*** p < 0.001.  
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As Fluo-3 and Calcein are transported by MDR1 as well as by MRP transporters, we added 
Ageladine A to study a possible inhibitory effect of this compound on the transporters involved. 
However, Ageladine A had no effect on the accumulation of either fluorophore by the worms (Figure 4). 
Figure 4. Effect of Ageladine A on the accumulation of fluorescent dyes in M. lignano. 
The worms were exposed to Calcein am (5 μM, A), Fluo-3am (5 μM, B), Rhodamine B  
(5 μM, C), or CMFDA (10 µM, D) in the absence or the presence of Ageladine A  
(Ag, 5 μM). 
 
In order to confirm the lack of effect of Ageladine A on MRP transporters, we used an established 
model to investigate the function of these transporters: the GSH export from cultured brain  
astrocytes [22]. Ageladine A was not toxic to astrocytes and did not significantly increase the 
extracellular lactate dehydrogenase activity, even in concentrations of up to 100 µM, demonstrating 
that the cell membrane integrity of the astrocytes was not compromised by Ageladine A (Figure 5D). 
MK571 clearly inhibited GSH transport from astrocytes (Figure 5A,C), whereas Ageladine A did not 
significantly inhibit GSH export (Figure 5B,C). 
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Figure 5. Effects of Ageladine A on the viability and on the GSH export from cultured 
astrocytes. The cells were incubated for up to 3 h in incubation buffer without (control) or 
with 50 µM MK571 (A) or without or with Ageladine A in the concentrations indicated (B). 
The export rates for glutathione (GSH) (C) were calculated from the almost linear 
increases in extracellular GSH content (A,B) between 30 and 180 min. The extracellular 
lactate dehydrogenase (LDH) activity was determined after 3 h of incubation (D). 
Statistical significance of the difference between data obtained from cells that had been 
treated without or MK571 (* p < 0.05) were calculated by the t-test. No significant 
differences (ANOVA with a Dunnet’s post hoc test) compared to control cells (D-control: 
1% DMSO as solvent control) were found for Ageladine A-treated cells (p > 0.05). 
Experiments were performed on three (A–C) or two (D) individually prepared cultures. 
 
3. Discussion 
The question we addressed was how M. lignano deals with exposure to toxins and toxicants. Using 
various fluorescent dyes as reporters with well-established pharmacologically inhibitors of multidrug 
transporters, we demonstrate the presence of functional multidrug resistance proteins in the worms that 
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and MRP1. These results demonstrate that the fluorescent dyes are taken up into the worms. We 
further ruled out the possible inhibition of multidrug resistance transporter-mediated dye export from 
M. lignano by the sponge derived secondary metabolite Ageladine A and showed that Ageladine A has 
no direct toxic or lytic effect on the worms for a minimum of a week. 
The flatworms appear to have the ability to quickly and sustainably remove acetoxymethyl ester 
dyes as xenobiotic surrogates. In many experiments, staining of animals with such dyes was weak in 
the absence of inhibitors of the multidrug resistance transporters, indicating efficient constitutive 
export activity. Functional expression and a baseline activity support the idea of an evolutionary 
adaptation to toxin exposure from the diatoms contained in the diet and from additional uptake of 
anthropogenic pollutants at the Adriatic coast. 
3.1. Multidrug Resistance Transporters 
The structure and function of MDR1 and MRP1 are highly conserved in evolution [42–49]. An EST 
(expressed sequence tag) database for M. lignano [50] annotated the MDR (P-glycoprotein) sequence 
blasting against rodent genes [51]. Now, our data experimentally confirm the presence of functional 
multidrug resistance transporters in M. lignano that have a similar pharmacological profile as those 
known in mammals. Typical substrates of these transporters are hydrophobic or amphipatic compounds 
reaching 300–2000 Da in mass [52] fitting well to the substrates we have used in our study. 
Seelig [53] compared a hundred compounds which were tested to be MDR1 substrates and 
described that two or three electron donor/hydrogen bonding acceptor groups are required for an 
interaction with MDR1. The spatial distance between the electron donor groups has to be either  
2.5 ± 0.3 Å (Type I) or 4.6 ± 0.6 Å (Type II) to bind to the transmembrane sequence of MDR1 which 
contains many amino acids with hydrogen bonding donor side chains. The strength of the hydrogen 
bonds formed by substrate and transporter defines the dissociation of the transporter-substrate  
complex [54]. Therefore, a molecule having many hydrogen bonding sites operates as an inhibitor in 
most cases [54]. Furthermore, substrates containing planar aromatic rings and tertiary amino groups 
favor an interaction with MDR1 [55]. To understand why Ageladine A does not have an effect on 
multidrug resistance transporters and, furthermore, why it is not a substrate of such transporters, it is 
necessary to consider the molecular interaction between substrate and transporters. The ABC 
transporter function is directly linked to the cellular energy level which is a function of the rate of ATP 
hydrolysis to ADP and Pi [56]. 
Seawater and F/2 medium have a pH value around 8.1 and in this neutral to slightly basic 
environment Ageladine A is uncharged and hydrophobic, turning it into a membrane-permeable  
dye [11]. Inside acidic organelles, e.g., lysosomes, the molecule becomes charged (Figure 6). MDR1 is 
expected to recognize its substrates within the cell membrane before it reaches the cytoplasm to 
prevent the cellular entry of drugs [56,57]. This implies that only uncharged Ageladine A from a 
neutral or basic environment can theoretically be transported by MDR1. The charged microspecies of 
Ageladine A, “trapped” inside acid organelles, are not available for multidrug resistance transport in 
the cell membrane. This could explain the long lasting fluorescence of Ageladine A within the worms’ 
cells. Furthermore, Ageladine A features two electron donor groups (Figure 6) but their spatial 
distance seems to be too large to interact with the MDR1 hydrogen bonding donor side chains. The 
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approximate distance between the nitrogen atom of the guanidine and the pyrrole ring (calculated at 
the B3LYP/6-311+G(d,p) level of theory [58]) is 585 pm, and this distance does not rank Ageladine A 
among either type I or type II substrate of Seeligs classification [53]. These considerations argue 
strongly against the protonated micro-species of Ageladine A to be a MDR1 substrate, which is in line 
with the results of our experiments. 
Figure 6. Mesomeric microspecies of Ageladine A. The distribution of the microspecies of 
Ageladine A depends strongly on the pH of the environment. The pyrrole is shown as 
residual structure (R). Two uncharged mesomeric microspecies are dominant at a pH of 
approximately 7–9. The single protonated microspecies are present at a pH of 
approximately 5–7, whereas the twice positively charged microspecies can be found at a 
pH of approximately 3–5 (Bickmeyer et al. 2010 (supplemental data in [11])).  
 
The MRP transporters are described as organic anion transporters. Jedlitschky [59] and coworkers 
found that most of the anionic substrates are conjugates of glutathione, glucuronate, or sulfate. The 
highly charged substrates of MRP are not able to penetrate cell membranes [32,59]. For studying MRP 
in intact cells, hydrophobic precursors of the substrates are used which are converted intracellularly 
into anions [59]. As Ageladine A is an amphipathic molecule and tends to be neutral or cationic at the 
physiological pH of organic tissues, it does not meet the main requirement for being a MRP substrate, 
the anionic character. In contrast, a potentially formed conjugate of Ageladine A with glutathione, 
glucuronate, or sulfate could enable extrusion of the alkaloid from cells as such conjugates are well 
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known as substrates of MRPs [60]. However, such a conjugation and export is unlikely to occur as the 
cellular fluorescence of Ageladine A is maintained over many days in the worms. Possibly the marine 
natural alkaloid compound Ageladine A was optimized in evolution to avoid export by multidrug 
resistance transporters. As control for a potential effect of Ageladine A on MRP-mediated transport, 
we investigated the GSH export from cultured brain astrocytes. Ageladine A did even in 
concentrations of up to 100 µM not compromise the viability of astrocytes which is consistent with the 
reported lack of Ageladine A toxicity on cultured neurons [11]. In contrast to MK571, Ageladine A did 
not inhibit MRP1-mediated export of GSH in astrocytes, which is consistent with the view that 
Ageladine A is not a substrate of MRP1. 
Ageladine A does not seem to either reduce the ATPase activity or compete against normal 
substrates for an interaction with multidrug resistance transporters. Furthermore, our results indicate 
that Ageladine A cannot be considered as a catalytic substrate. The assays of our study only show the 
retention of the protonated fluorescent micro-species of Ageladine A. A possible extrusion of 
uncharged lipophilic micro-species of Ageladine A cannot be assessed through the use of this assay. 
Our results indicate that the protonated form of Ageladine A is a non-substrate of multidrug resistance 
transporters that interacts neither with the ATPase activity nor with the substrate binding domains. 
The multidrug resistance transporter inhibitors used in our study were developed for medical 
purposes. MK571, for example, was discovered as a competitive leukotriene D4 receptor inhibitor in 
human tumor cells [30]. Probenecid was introduced in 1950 as “Benemid” and suggested as an adjunct 
to chemotherapy [61]. It was later used to study the effects of uric acid secretion and associated 
changes of blood levels in gout patients [62]. Furthermore, Verapamil was used to improve angina 
pectoris pain [63]. Thus, it is remarkable that all three inhibitors showed an effect in the flatworm  
M. lignano, which is not closely related to mammals. The study of Scherer et al. [41] showed a similar 
effect of Verapamil on transporters of the diatom Thalassiosira rotula. Our results support the fact that 
multidrug resistance transporters are highly conserved structures in nature. 
3.2. Reporter Dyes 
Sarkadi and Müller introduced Calcein am as “the dye of choice” for fluorescent reporter assays [64]. 
The hydrophobic non-fluorescent Calcein am is a substrate of MDR1, whereas the free hydrophilic 
form is trapped inside the cells and is no longer subject to transport. In MDR1 expressing cells, 
Calcein am is extruded before it can be intracellularly converted into its fluorescent form. 
Consequently, the Calcein accumulation is slow, unless a transport inhibitor is present. The free 
Calcein does not bind to proteins and is independent of changes in pH and ion concentrations [64]. 
Furthermore, it was shown that both Calcein am and free Calcein are transported by MRPs [32,33]. 
Fluo-3 am and Fura-2 am are further fluorescent anions which are used to determine MDR1 and MRP 
expression levels and to screen for modulators of the transporters [56]. 
Rhodamine B was additionally used as a reported dye. The literature is controversial about the 
function of Rhodamine B in MDR1- or MRP-mediated transport. Minier and Moore [65] suggest a 
correlation of Rhodamine B retention and expression levels of proteins which are immunorelated to 
MDR1 in mussel hemocytes. Furthermore, a Rhodamine-binding site was identified in MDR1 [66]. 
Several Rhodamine dyes, such as Rhodamine B, are transported by MDR1 and also stimulate the 
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ATPase activity. According to our results, Rhodamine B does not seem to be either a MDR1 or a  
MRP substrate, because the presence of Verapamil, Probenecid, or MK571 inhibited the transporter 
function, but did not enhance Rhodamine B fluorescence. This is in line with results of previous 
studies [67] showing that Rhodamine B is either a very poor or non-substrate of MDR1 and MRP1. 
Structural and functional differences of transporters of different species may be responsible for 
controversial findings concerning Rhodamine B transport [68]. 
CMFDA is not mentioned to be a substrate of multidrug resistance transporters in the literature and 
is a good long-term cell tracker. The cell-impermeant S-conjugate does not leak out of cells [69]. In 
our experiments, the cellular fluorescence was not influenced by the presence of the multidrug 
resistance transporter inhibitors, suggesting that this dye is a non-substrate of multidrug resistance 
transporters in M. lignano. 
4. Experimental Section 
4.1. Animals and Cell Culture 
The plathyhelminth M. lignano (DV-1 line) was cultured at 20 °C with 95% humidity and a 14/10 
day-night cycle in glass dishes with nutrient-enriched artificial seawater (Guillard’s F2 medium) as 
previously described by Ladurner et al. [1]. Animals were fed once per week with the diatom Nitzschia sp. 
Astroglia-rich primary cell cultures were obtained from the brains of neonatal Wistar rats. The cells 
were obtained as previously described [70] and seeded in 24 well plates at a density of 300,000 cells 
per well in 1 medium (90% DMEM, 10% fetal calf serum, 20 units/mL penicillin G, 20 μg/mL 
streptomycin sulfate). Medium was changed every week. Cells were maintained in a cell incubator 
(Sanyo, Osaka, Japan) in a humidified atmosphere containing 10% CO2. Triplicate experiments were 
performed on two-week-old cell cultures. 
4.2. Chemicals 
Six different fluorescent dyes were used. Ageladine A (exc: 365 nm, em: 420–480 nm) and  
the calcium indicators Calcein acetoxymethylester (Calcein am, Invitrogen; exc: 467 nm, em:  
500–540 nm), Fura-2 acetoxymethylester (Fura-2 am, Sigma-Aldrich; exc: 360 nm, em: 480–540 nm), 
and Fluo-3 acetoxymethylester (Fluo-3 am, Invitrogen; exc: 488 nm, em: 510–550 nm) were used at a 
common concentration of 5 μM. All of the three calcium indicator dyes are known to be substrates of 
MDR1 [25,43,44] and MRPs [33,41,43,45]. 
Cell Tracker Green 5-chloromethylfluorescein diacetate (CMFDA, Invitrogen; exc: 488 nm, em: 
500–550 nm concentration: 10 µM) and Rhodamine B (Sigma-Aldrich; exc: 561 nm, em: 570–620 nm; 
concentration: 5 µM) were also used. 
MK571 (Biomol) was applied in a final concentration of 50 μM. It has been considered to be a 
specific inhibitor of MRP1 transporters [30]. Probenecid was used at a concentration of 2.5 mM, and 
Verapamil, one of the most potent competitive MDR1 inhibitors [46], was used at a final concentration 
of 25 µM. 
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4.3. Fluorometric Measurements 
The fluorescence in M. lignano was monitored with a confocal laser scanning microscope Leica 
TCS SP5. The microscope was equipped with a multi-photon laser (MaiTai, DeepSee, Newport 
Spectra-Physics), an argon-laser (488 nm), and a helium-neon-laser (561 nm). For analyzing 
differences in fluorescence, the region-of-interest function of the software Leica LAS AF was used, 
with five transects drawn through each animal’s body covering all tissues. 
4.4. Stability of Staining 
The fluorescence intensity of six dyes was investigated for up to nine days in stained M. lignano. 
The experimental animals were transferred to Petri dishes containing fresh F/2 medium (without food) 
to avoid fluorescence interference from diatoms, etc. Animals were placed on slides filled with 100 μL 
F/2 medium containing the respective fluorescent dye. After 1.5 h of incubation, animals were 
transferred to fresh F/2 medium without fluorescent dyes. To avoid contamination and evaporation of 
the medium, slides were kept in plastic boxes sealed with foil. To measure the fluorescence intensity 
animals were transferred into Utermöhl chambers containing 100 μL F/2 medium with 5 µL of a 
relaxing solution (2 g MgCl2 in 1 mL filtered artificial seawater) to facilitate the scanning. 
4.5. Inhibition of Multidrug Resistance Transporters 
The MDR1-inhibitor Verapamil and the MRP1 inhibitors MK571 or Probenecid were added to the 
F/2 medium containing one of the listed fluorescent dyes (Ageladine A, Calcein am, Fura-2 am,  
Fluo-3 am, CMFDA or Rhodamine B). An inhibition of the transporters should cause a stronger 
accumulation of fluorescence substrates in the worms by inhibiting dye export. Changes in 
fluorescence intensity were measured with a Leica SP5 confocal microscope after 1.5 h of incubation. 
Furthermore, Ageladine A was added to the medium containing fluorescent dyes to test for transporter 
inhibition of this compound. Ageladine A and Fura-2 am have overlapping excitation and emission 
ranges, which could lead to fluorescence interference among dyes. Therefore, combined staining of 
Fura-2 together with Ageladine A was avoided. 
4.6. Determination of Glutathione Content and Viability of Treated Astrocytes 
The extracellular amount of glutathione (GSH; determined as GSx (=amount of GSH + 2 × amount 
of glutathione disulfide)) was analyzed to test for a potential effect of Ageladine A on  
MRP1-mediated GSH export. Astrocytes were incubated in incubation buffer without (control) or with 
1% DMSO (solvent control), 50 μM MK571, 1 μM, 10 μM, or 100 μM Ageladine A for up to 3 h as 
previously described and extracellular GSH was determined as described previously [71] in microtiter 
plates, according to the method originally described by Tietze [70]. Cell viability was determined as 
previously described [22] by determining the extracellular lactate dehydrogenase (LDH) activity after 
incubation and comparing it with that of astrocytes that had been totally lysed by a 30 min incubation 
in 1% Triton X-100. The protein content of the cells was determined by the Lowry methods [72] using 
bovine serum albumin as standard protein. 
  




Fluorescence intensities from five regions of interest per animal were pooled, averaged, and 
considered as one value. Each treatment group consisted of 5–10 individuals. Results are presented as 
means ± SE. Data generated by lactate dehydrogenase and GSH assays measurements represent  
means ± SD of three independent experiments. General data processing was conducted with Microsoft 
Excel 2010. The statistical tests ANOVA and nonparametric T-tests were performed, using the 
software IBM SPSS 20. 
5. Conclusions 
The presented work is a multidrug resistance study on the living flatworms M. lignano, and 
provides evidence for the presence of at least two classes of highly evolutionary conserved multidrug 
resistance transporters that have the pharmacological profile of MDR1 and MRP1. The results shown 
disprove our original hypothesis that Ageladine A may have an inhibitory effect on MDR1- and/or  
MRP-mediated export processes. Nevertheless, the lack of export of Ageladine A together with the 
apparent low toxicity of this compound make Ageladine A a highly useful tool for life imaging of 
marine transparent animals and cells. 
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